The Histologic Type and Stage Distribution of Ovarian Carcinomas of Surface Epithelial Origin
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Advances over the past decade suggest a need to reassess the distribution of ovarian surface epithelial tumors. A series of 220 consecutive invasive ovarian carcinomas, including carcinosarcomas and peritoneal carcinomas, was reviewed. Notable findings include: 7% of tumors were carcinosarcomas; 22% of cases of peritoneal serous carcinomatosis were of peritoneal origin; <3% of cases were mucinous carcinomas; and only one malignant Brenner tumor (0.5%) and no pure transitional cell carcinomas were identified. If peritoneal carcinomas, carcinosarcomas, and mixed carcinomas with a serous component are combined with serous carcinomas, this group accounts for 78% of all cases and 87% of advanced stage cases, suggesting a greater uniformity to epithelial ovarian cancer than previously appreciated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thompson, L., Chang, B., & Barsky, S. H. (1996) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199603000-00003 · Cited by 365
Studies on Bilirubin in Amniotic Fluid: With Special Reference to Liver Function Tests
Ojala, A. (1971) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.3109/00016347109157182 · Cited by 271
Riopel, M. A., Ronnett, B. M., & Kurman, R. J. (1999) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199906000-00001 · Cited by 258
Self-citationA case-control study of epithelial ovarian cancer
Hartge, P., Schiffman, M. H., Hoover, R., McGowan, L., Lesher, L., & Norris, H. J. (1989) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(89)90221-4 · Cited by 206
Sreenan, J. J., & Hart, W. R. (1995) · PubMed · Cited by 199
Sreenan, J. J., & Hart, W. R. (1995) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199506000-00007 · Cited by 199
Cigarette Smoking and Epithelial Ovarian Cancer by Histologic Type
Marchbanks, P. A., Wilson, H. G., Bastos, E., Cramer, D. W., SCHILDKRAUT, J. M., & Peterson, H. B. (2000) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(99)00531-1 · Cited by 94
Haber, D. (2002) · New England Journal of Medicine · doi:10.1056/nejmed020044 · Cited by 86
Cited by
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Evaluating cell lines as tumour models by comparison of genomic profiles
Domcke, S., Sinha, R., Levine, D. A., Sander, C., & Schultz, N. (2013) · Nature Communications · doi:10.1038/ncomms3126 · Cited by 1,418
Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brünner, N., Chan, D. W., Babaian, R., Bast, R. C., Dowell, B., Esteva, F. J., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.105601 · Cited by 1,129
The Mammalian Ovary from Genesis to Revelation
Edson, M. A., Nagaraja, A. K., & Matzuk, M. M. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0012 · Cited by 820
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016
Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D'Amico, T. A., Dilling, T. J., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0031 · Cited by 736
Cho, K. R., & Shih, I.-M. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092246 · Cited by 694
McCluggage, W. G. (2011) · Pathology · doi:10.1097/pat.0b013e328348a6e7 · Cited by 497
New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact
Levanon, K., Crum, C., & Drapkin, R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1107 · Cited by 412
“early stage (stages I and II), a statistic which reflects grimly on the survival figures.(16,17) Nearly 22,500 women are diagnosed with ovarian”
BackgroundMulticellular spheroids in ovarian cancer metastases: Biology and pathology
Shield, K., Ackland, M. L., Ahmed, N., & Rice, G. E. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.11.032 · Cited by 412
Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas
Köbel, M., Kalloger, S. E., Huntsman, D. G., Santos, J. L., Swenerton, K. D., Seidman, J. D., & Gilks, C. B. (2010) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e3181c042b6 · Cited by 398
Self-citationHigh-grade serous ovarian cancer arises from fallopian tube in a mouse model
Kim, J., Coffey, D. M., Creighton, C. J., Yu, Z., Hawkins, S. M., & Matzuk, M. M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117135109 · Cited by 398
A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas
Soragni, A., Janzen, D. M., Johnson, L. M., Lindgren, A. G., Thai-Quynh Nguyen, A., Tiourin, E., Soriaga, A. B., Lu, J., Jiang, L., Faull, K. F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.002 · Cited by 341
“About 80% of all ovarian cancers are of the high-grade serous type, mostly diagnosed at advanced stages with poor long-term prognosis (Seidman et al., 2004).”
BackgroundOvarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology
Morgan, R. J., Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Behbakht, K., Chen, L.-M., Copeland, L., Crispens, M. A., DeRosa, M., Dorigo, O., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0122 · Cited by 311
Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer
Xu, J., Fang, Y., Chen, K., Li, S., Tang, S., Ren, Y., Cen, Y., Fei, W., Zhang, B., Shen, Y., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0296 · Cited by 308
Characterization and proteomic analysis of ovarian cancer-derived exosomes
Liang, B., Peng, P., Chen, S., Li, L., Zhang, M., Cao, D., Yang, J., Li, H., Gui, T., Li, X., et al. (2013) · Journal of Proteomics · doi:10.1016/j.jprot.2012.12.029 · Cited by 308
Ovarian Cancer Pathogenesis: A Model in Evolution
Karst, A. M., & Drapkin, R. (2010) · Journal of Oncology · doi:10.1155/2010/932371 · Cited by 298
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
Press, J. Z., De Luca, A., Boyd, N., Young, S., Troussard, A., Ridge, Y., Kaurah, P., Kalloger, S. E., Blood, K. A., Smith, M., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-17 · Cited by 287
Modeling High-Grade Serous Ovarian Carcinogenesis from the Fallopian Tube
Karst, A. M., Levanon, K., & Drapkin, R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017300108 · Cited by 280
Cell Origins of High-Grade Serous Ovarian Cancer
Kim, J., Park, E., Kim, O., Schilder, J., Coffey, D., Cho, C.-H., & Bast, R. (2018) · Cancers · doi:10.3390/cancers10110433 · Cited by 264
Creighton, C. J., Fountain, M. D., Yu, Z., Nagaraja, A. K., Zhu, H., Khan, M., Olokpa, E., Zariff, A., Gunaratne, P. H., Matzuk, M. M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3875 · Cited by 264
Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment
Rojas, V., Hirshfield, K., Ganesan, S., & Rodriguez-Rodriguez, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122113 · Cited by 254
Ovarian carcinoma pathology and genetics: recent advances
Gilks, C. B., & Prat, J. (2009) · Human Pathology · doi:10.1016/j.humpath.2009.04.017 · Cited by 249
“Transitional cell carcinomas without a Brenner component vary widely in frequency in different case series [80,81] and cannot be reproducibly distinguished from HGSCs based on clinical [82] or molecular features [83-86].”
BackgroundPAX8 Reliably Distinguishes Ovarian Serous Tumors From Malignant Mesothelioma
Laury, A. R., Hornick, J. L., Perets, R., Krane, J. F., Corson, J., Drapkin, R., & Hirsch, M. S. (2010) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181da7687 · Cited by 230
Morice, P., Gouy, S., & Leary, A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1813254 · Cited by 227
Anglesio, M. S., Kommoss, S., Tolcher, M. C., Clarke, B., Galletta, L., Porter, H., Damaraju, S., Fereday, S., Winterhoff, B. J., Kalloger, S. E., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4088 · Cited by 198
Mucinous Tumors of the Ovary: Current Thoughts on Diagnosis and Management
Brown, J., & Frumovitz, M. (2014) · Current Oncology Reports · doi:10.1007/s11912-014-0389-x · Cited by 188
“In contrast to serous ovarian carcinomas, in which only 4 % of patients are stage I at diagnosis, 83 % of mOCs are stage I at the time of diagnosis [22].”
BackgroundMy approach to and thoughts on the typing of ovarian carcinomas
McCluggage, W. G. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2007.049478 · Cited by 166
Mismatch repair deficiency in ovarian cancer — Molecular characteristics and clinical implications
Xiao, X., Melton, D. W., & Gourley, C. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.12.003 · Cited by 89
Bartoletti, M., Musacchio, L., Giannone, G., Tuninetti, V., Bergamini, A., Scambia, G., Lorusso, D., Valabrega, G., Mangili, G., Puglisi, F., et al. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102298 · Cited by 22
Integrated genomic analyses of ovarian carcinoma
The Cancer Genome Atlas Research Network (2011) · Nature · doi:10.1038/nature10166 · Cited by 129
Metadata
- Authors
- Seidman, J. D., Horkayne-Szakaly, I., Haiba, M., Boice, C. R., Kurman, R. J., & Ronnett, B. M.
- Venue
- International Journal of Gynecological Pathology
- Published
- 2004-01
- Volume
- 23
- Issue
- 1
- Pages
- 41-44
- ISSN
- 0277-1691 (ISSN-L)
- OpenAlex
- W2088899370
- Cited by
- 554
- References
- 8
- FWCI
- 5.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.